Takeda Pharmaceutical Co. Ltd. has entered into a definitive agreement to acquire Inviragen, Inc. for an upfront payment of $35 million, and future payments of as much as $215 million for clinical development and commercial milestones. Inviragen, headquartered in Fort Collins, CO, with facilities in Madison, WI and Singapore, specializes in the development of vaccines for emerging infectious diseases, including dengue and hand, foot and mouth disease (HFMD).   Inviragen’s lead candidate, DENVax,...